I promised a reference for which talk at ASCO discussed the diminishing returns for

[Lani]

2nd,3rd, 4th,and so on line chemotherapy for recurrent metastatic breast cancer and how that differed for her2 targeted therapies for her2+ patients.

It was from


Therapeutic Options for Treatment Refractory Breast Cancer: Discussion
Harold J. Burstein, MD, PhD
Discussant

Given on the last day of ASCO

It is a video included in the virtual meeting which will be available free @ the beginning of December.